Journal of advanced research · 2025
Arachidonic acid metabolism in spinal cord injury.
СтатьяОбзорПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yao Xue, Liu Xinjie, Cai Wenbin, Ning Guangzhi, Zhang Xu, Zhou Kailiang, Feng Shiqing
Аннотация
BACKGROUND: Spinal cord injury (SCI) initiates a cascade of secondary pathological processes significantly impairs functional recovery and leads to complications such as neuropathic pain. Arachidonic acid (AA) and its metabolites play crucial roles through various metabolic pathways. These pathways contribute to neuroinflammation, tissue damage, and functional impairment following SCI.
AIM: We aim to provide a comprehensive outline on AA metabolic pathways, enzymes and signaling cascades in spinal cord injury pathophysiology, in order to develop new perspectives in treatment and diagnosis.
KEY SCIENTIFIC CONCEPTS: We present a comprehensive review on AA metabolism and pathways in the different pathology process of SCI, such as neuronal loss, demyelination, neuropathic pain and neuroinflammation with different cell types involved. We also discussed the complex interactions of AA metabolites pose challenges for the development of effective therapies. Finally, we outlooked future research directions aimed at optimizing AA-targeted treatments and expanding their clinical applicability to enhance recovery in patients with SCI.
AIM: We aim to provide a comprehensive outline on AA metabolic pathways, enzymes and signaling cascades in spinal cord injury pathophysiology, in order to develop new perspectives in treatment and diagnosis.
KEY SCIENTIFIC CONCEPTS: We present a comprehensive review on AA metabolism and pathways in the different pathology process of SCI, such as neuronal loss, demyelination, neuropathic pain and neuroinflammation with different cell types involved. We also discussed the complex interactions of AA metabolites pose challenges for the development of effective therapies. Finally, we outlooked future research directions aimed at optimizing AA-targeted treatments and expanding their clinical applicability to enhance recovery in patients with SCI.